Pumosetrag Hydrochloride is a selective 5-HT3 receptor agonist primarily used in medical research for gastrointestinal motility disorders. It activates peripheral 5-HT3 receptors in the gut to promote peristalsis and improve bowel function, positioning it as a candidate for treating conditions such as irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Its design minimizes central nervous system penetration, thereby reducing common side effects associated with 5-HT3 modulation like nausea and emesis. Clinical studies continue to assess its efficacy, safety profile, and therapeutic potential.